We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
AbD Serotec and Spinreact Sign Supply Agreement for Antibodies used in Clinical Diagnostic Kits
News

AbD Serotec and Spinreact Sign Supply Agreement for Antibodies used in Clinical Diagnostic Kits

AbD Serotec and Spinreact Sign Supply Agreement for Antibodies used in Clinical Diagnostic Kits
News

AbD Serotec and Spinreact Sign Supply Agreement for Antibodies used in Clinical Diagnostic Kits

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "AbD Serotec and Spinreact Sign Supply Agreement for Antibodies used in Clinical Diagnostic Kits"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

MorphoSys AG has announced that its research and diagnostic antibody segment AbD Serotec and Spinreact S.A., a Spanish biotechnology company, have signed a supply agreement.

Initially, the agreement covers the use of two antibodies which Spinreact will incorporate in a series of clinical diagnostic kits. AbD Serotec will continuously supply Spinreact with antibody material. Financial details of the agreement were not disclosed.

Dr Josep Puig, Chief Executive Officer of Spinreact, said "Spinreact is delighted to announce this agreement with AbD Serotec - an industry leader in providing tailored antibodies for research and diagnostic applications. The fast turn-around in antibody production offered by AbD Serotec, together with the high quality of the resulting antibodies, will help accelerate the process of development and validation, allowing Spinreact to bring new clinical diagnostic reagents for human diseases to the market in the shortest possible timeframe."
Advertisement